Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Transfusion. 2012 Apr;52(4):849-59. doi: 10.1111/j.1537-2995.2011.03346.x. Epub 2011 Oct 7.
Alloantibodies are a clinically significant sequelae of platelet (PLT) transfusion, potentially rendering patients refractory to ongoing PLT transfusion support. These antibodies are often IgG class switched, suggesting the involvement of CD4+ T-cell help; however, PLT-specific CD4+ T cells have not been visualized in vivo, and specifics of their stimulation are not completely understood.
A murine model of alloimmunization to transfused PLTs was developed to allow in vivo assessment and characterization of CD4+ T cells specific for PLT major histocompatibility complex (MHC) alloantigen. PLTs were harvested from BALB/c mice, filter leukoreduced, and transfused into C57BL/6 recipients. PLT-specific CD4+ T-cell responses were visualized by using a T-cell receptor transgenic mouse that detects peptide from donor MHC I presented on recipient MHC II. Antibody responses were determined by indirect immunofluorescence using BALB/c donor targets.
C57BL/6 recipients of BALB/c leukoreduced PLT transfusions produced BALB/c antibodies, with proliferation of antigen-specific CD4+ T cells seen in the spleen but not lymph nodes or liver. Depletion of recipient CD4+ cells or splenectomy independently abrogated the alloantibody response.
We report a novel model to study antigen-specific CD4+ T cells during alloimmunization to PLT transfusion. The presented data support a critical role for CD4+ T-cell help in the humoral response to PLT transfusion and establish the spleen as a required microenvironment for effective CD4+ T-cell priming against donor PLT-derived MHC I.
同种异体抗体是血小板 (PLT) 输注的一种具有临床意义的后遗症,可能使患者对持续的 PLT 输注支持产生耐药性。这些抗体通常是 IgG 类别转换的,这表明 CD4+T 细胞的辅助作用;然而,尚未在体内可视化 PLT 特异性 CD4+T 细胞,并且其刺激的具体细节尚不完全清楚。
开发了一种用于输注 PLT 引起同种免疫的小鼠模型,以允许在体内评估和表征针对 PLT 主要组织相容性复合物 (MHC) 同种抗原的 CD4+T 细胞。从 BALB/c 小鼠中收获 PLT,过滤白细胞减少,并输注到 C57BL/6 受体中。通过使用检测供体 MHC I 肽在受体 MHC II 上呈递的 T 细胞受体转基因小鼠来可视化 PLT 特异性 CD4+T 细胞反应。使用 BALB/c 供体靶标通过间接免疫荧光法测定抗体反应。
接受 BALB/c 白细胞减少 PLT 输注的 C57BL/6 受体产生 BALB/c 抗体,在脾脏中可见抗原特异性 CD4+T 细胞增殖,但在淋巴结或肝脏中未见。受体 CD4+细胞耗竭或脾切除术均可独立消除同种抗体反应。
我们报告了一种研究 PLT 输注同种免疫期间抗原特异性 CD4+T 细胞的新型模型。所提供的数据支持 CD4+T 细胞辅助在 PLT 输注的体液反应中的关键作用,并确立脾脏是针对供体 PLT 衍生 MHC I 进行有效 CD4+T 细胞启动的必需微环境。